Synthetic Biology’s Major Pain Point: Scale
While there are numerous SynBio startups that have reached unicorn status, many of them haven’t produced a single molecule. Those that have a product can’t successfully scale. In this panel, industry experts break down how both SynBio companies and investors can address this issue to effectively bring new solutions to the market.
Programming descriptions are generated by participants and do not necessarily reflect the opinions of SXSW.